Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Pricing

Thumbnail
August 12, 2020

Moderna shows the value of bulk-buying

The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.

Thumbnail
July 30, 2020

Astra shakes things up with Covid-19 pricing disclosure

By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.

Article image
Vantage logo
September 26, 2019

How Labour’s UK generic drugs plan could have been better

Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.

Article image
Vantage logo
September 23, 2019

Pricing questions remain as Novo gets the nod for oral sema

Novo Nordisk says that oral semaglutide’s list price will be “similar” to Ozempic’s, but it will be a while before its true cost becomes apparent.

Article image
Vantage logo
August 16, 2019

Bayer could become the latest casualty of Roche’s targeted pricing

Roche’s lower price tag for its targeted cancer therapy Rozlytrek could – intentionally or not – hit one of Bayer’s big hopes hard.

Article image
Vantage logo
May 07, 2019

Pfizer shoots for a high price with tafamidis

Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?

Article image
Vantage logo
April 10, 2019

Peanut therapy makers face pricing pushback

An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…

Article image
Vantage logo
March 14, 2019

Rebate ban would not necessarily equal savings, Icer says

An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.

Article image
Vantage logo
March 04, 2019

Lilly takes a leaf out of Mylan’s book to defuse insulin price complaints

Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.

Article image
Vantage logo
February 27, 2019

Big pharma execs decry rebates, but how big might list price cuts be?

Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.

Article image
Vantage logo
February 11, 2019

Regeneron and Sanofi play follow the leader on Praluent pricing

Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.